Sunshine Biopharma, Inc.
$1.02
▼
-5.02%
2026-04-21 09:18:01
sunshinebiopharma.com
NCM: SBFM
Explore Sunshine Biopharma, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$5.05 M
Current Price
$1.02
52W High / Low
$2.43 / $0.95
Stock P/E
—
Book Value
$5.31
Dividend Yield
—
ROCE
-23.97%
ROE
-25.68%
Face Value
—
EPS
$-1.44
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
50
Beta
1.6
Debt / Equity
3.53
Current Ratio
4.17
Quick Ratio
2.08
Forward P/E
0
Price / Sales
0.13
Enterprise Value
$-3.4 M
EV / EBITDA
0.82
EV / Revenue
-0.09
Rating
Strong Buy
Target Price
$5.6
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | BioAge Labs, Inc. | $18.8 | — | $820.58 M | — | -33.77% | -27.09% | $24 / $3.63 | $7.28 |
| 2. | Aytu BioPharma, Inc. | $2.58 | — | $27.69 M | — | 4.15% | -1.09% | $3.06 / $0.98 | $1.32 |
| 3. | Akebia Therapeutics, Inc. | $1.43 | — | $381.73 M | — | 11% | 64.49% | $4.08 / $1.14 | $0.12 |
| 4. | Zoetis Inc. | $118.25 | 19.63 | $49.71 B | 1.64% | 27.18% | 65.99% | $172.23 / $113.29 | $7.84 |
| 5. | Talphera, Inc. | $0.78 | — | $40.17 M | — | -52.04% | -1.15% | $1.57 / $0.38 | $0.34 |
| 6. | Phibro Animal Health Corporation | $56.51 | 24.91 | $2.29 B | 0.85% | 10.35% | 31.8% | $60.08 / $16.16 | $8.2 |
| 7. | Incannex Healthcare Inc. | $3.84 | — | $51 M | — | — | -1.3% | $49.8 / $2.4 | $6.13 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 8.58 M | 9.42 M | 9.41 M | 8.9 M | 9.59 M | — |
| Operating Profit | -1.66 M | -0.53 M | -0.99 M | -1.3 M | -2.04 M | — |
| Net Profit | -2.14 M | -0.88 M | -1.77 M | -1.18 M | -2.16 M | — |
| EPS in Rs | -0.44 | -0.18 | -0.36 | -0.24 | -0.44 | -0.94 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 36.31 M | 34.87 M | 24.09 M | 4.35 M |
| Operating Profit | -4.48 M | -5.81 M | -4.79 M | -8.67 M |
| Net Profit | -5.98 M | -5.13 M | -4.51 M | -26.74 M |
| EPS in Rs | -1.22 | -1.05 | -0.92 | -5.45 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 30.08 M | 30.56 M | 27.35 M | 29.24 M |
| Total Liabilities | 7.04 M | 7.06 M | 6.14 M | 7.62 M |
| Equity | 23.04 M | 23.5 M | 21.21 M | 21.63 M |
| Current Assets | 26.85 M | 25.97 M | 24.89 M | 27.31 M |
| Current Liabilities | 6.44 M | 6.31 M | 5.55 M | 6.93 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -5.33 M | -12.52 M | -8.78 M | -5.25 M |
| Investing CF | -0.84 M | -1.98 M | -0.66 M | -14.62 M |
| Financing CF | 4.75 M | 8.94 M | 3.43 M | 39.47 M |
| Free CF | -6.17 M | -14.5 M | -9.56 M | -5.55 M |
| Capex | -0.84 M | -1.98 M | -0.79 M | -0.3 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 44.75% | 454.42% | — | — |
| Earnings Growth % | -13.94% | 83.15% | — | — |
| Profit Margin % | -14.72% | -18.7% | -615.44% | — |
| Operating Margin % | -16.67% | -19.86% | -199.6% | — |
| Gross Margin % | 30.6% | 34.61% | 39.04% | — |
| EBITDA Margin % | -14.73% | -15.87% | -608.58% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-08-08 | 1:0.05 |
| 2024-04-17 | 1:0.01 |